Earlier reports provided direct clinical evidence: Malinge et al. (2007) described a novel activating JAK2 mutation in a DS patient with B-cell precursor ALL, while Kearney et al. (2009) documented the recurrent JAK2 R683 mutation together with multiple gene deletions [66,67]. Here, JAK2 is linked to acute lymphoblastic leukemia.